Company intelligence
ORIC Pharmaceuticals Inc.
Overcoming Resistance In Cancer
About ORIC Pharmaceuticals Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) Enozertinib (ORIC-114), a brain penetrant inhibitor designed to selectively target EGFR exon 20, HER2 exon 20 and EGFR atypical mutations in NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.
Verified activity
Signals from ORIC Pharmaceuticals Inc.
2 published signals
Presence & Recognition
ORIC Pharmaceuticals Inc. President and Chief Executive Officer Jacob Chacko, M.D., and Chief Financial Officer Dominic Piscitelli will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026, at 2:15 p.m. ET.
Reported by ORIC Pharmaceuticals Inc.
Research & Knowledge
ORIC Pharmaceuticals Inc. initiated Himalayas-1, a Phase 3 study evaluating experimental therapy rinzimetostat in combination with darolutamide in patients with metastatic castration-resistant prostate cancer.
Reported by ORIC Pharmaceuticals Inc.